GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OnKure Therapeutics Inc
OnKure, a privately held oncology company, is valued based on its progress in drug development. The potential post-IPO share price will depend on clinical trial results, regulatory approvals, and the commercial potential of its product portfolio.
Share prices of companies in the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer resistant to existing therapies. We categorize it as a "Cancer Treatment" company. The chart below shows how the market values companies working on next-generation cancer therapies.
Broad Market Index - GURU.Markets
OnKure Therapeutics is an oncology company developing targeted drugs for cancer treatment. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
OKUR - Daily change in the company's share price OnKure Therapeutics Inc
For OnKure Therapeutics Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
OnKure Therapeutics Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with OKUR's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
OnKure Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OnKure Therapeutics Inc
OnKure Therapeutics Inc.'s year-over-year performance is a story of targeted cancer drug development. Its 12-month market cap is entirely dependent on progress in clinical trials of its histone deacetylase (HDAC) inhibitors. Positive data could confirm the potential of its platform for developing a new class of oncology drugs.
Annual dynamics of market capitalization of the market segment - Cancer cure
OnKure, a private biotech company, develops drugs to treat cancer. Its growth depends on success in clinical trials. Its valuation dynamics reflect investors' confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OnKure Therapeutics is privately held and not publicly traded. Its ticker symbol, OKUR, is inactive. Analysis of its market performance is impossible. As a biotech company focused on cancer treatment, its value is determined solely by clinical trial results, not economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OnKure Therapeutics Inc
OnKure is an oncology company. Its monthly performance is typical for early-stage biotech companies: it depends entirely on progress in its scientific developments. News about preclinical studies, patents, and funding are the main catalysts.
Monthly dynamics of market capitalization of the market segment - Cancer cure
OnKure Therapeutics is a biotech company developing targeted drugs for cancer treatment. Success in this sector depends on scientific rigor and clinical trial results. The chart below reflects the overall investor sentiment regarding innovative oncology and their belief in personalized medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to illustrate how scientific news and the potential of its platform have driven its stock price movement completely independent of overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OnKure Therapeutics Inc
OnKure Therapeutics is an early-stage biotech company. Its hypothetical weekly stock price would be highly volatile, driven by news about preclinical studies, funding, and overall investor interest in its scientific platform and approach to cancer treatment.
Weekly dynamics of market capitalization of the market segment - Cancer cure
OnKure Therapeutics is an early-stage biotech company. Its hypothetical weekly stock price would be highly volatile, driven by news about preclinical studies, funding, and overall investor interest in its scientific platform and approach to cancer treatment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OnKure, a biotech company, would live in a world of its own. Its performance would be determined by clinical trial data. A chart comparing it to the S&P 500 would clearly demonstrate how the stock could rise or fall on company-specific events, completely ignoring what's happening in the broader market.
Market capitalization of the company, segment and market as a whole
OKUR - Market capitalization of the company OnKure Therapeutics Inc
OnKure Therapeutics' market capitalization chart, if it were to go public, would be a story about the development of a new generation of targeted cancer drugs. Its dynamics would reflect investor expectations for its scientific platform and early research data, as well as all the risks inherent in biotech companies working in oncology.
OKUR - Share of the company's market capitalization OnKure Therapeutics Inc within the market segment - Cancer cure
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for cancer treatment. Its share of the market capitalization of its oncology segment reflects the potential of its scientific platform. The chart below shows the valuation volatility typical for biotech companies, dependent on the progress of clinical trials.
Market capitalization of the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing drugs to treat oncology. The chart below shows the overall market capitalization of the oncology sector. It reflects the highly competitive and scientifically complex nature of this field, where each company seeks its own unique approach to fighting cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows the development of a targeted cancer therapy. OnKure Therapeutics is an early-stage biotech company. Its thin, volatile line will reflect any progress in preclinical and clinical trials. This is a visualization of the very first steps in creating a new drug.
Book value capitalization of the company, segment and market as a whole
OKUR - Book value capitalization of the company OnKure Therapeutics Inc
OnKure Therapeutics' book value reflects its scientific capital, which is focused on developing a new generation of targeted cancer drugs that target histone deacetylases (HDACs). This represents a cutting-edge scientific foundation. The chart below shows how the biotech company is accumulating resources for clinical testing of its innovative hypotheses in oncology.
OKUR - Share of the company's book capitalization OnKure Therapeutics Inc within the market segment - Cancer cure
OnKure Therapeutics is a biotech company developing targeted cancer drugs. Its assets are intellectual property. The chart shows the minimal share of physical assets, as it is an R&D company.
Market segment balance sheet capitalization - Cancer cure
Oncology drug development, as the BCap_Ges chart for biotech shows, is a science-intensive industry. OnKure Therapeutics operates in this environment, where capital is invested in clinical trials and patents rather than in plant construction.
Book value of all companies included in the broad market index - GURU.Markets
OnKure Therapeutics' book value represents capital invested in the development of next-generation targeted oncology drugs. It reflects the financial foundation that enables the company to conduct research and trials to transform scientific discoveries into tangible, real-world treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OnKure Therapeutics Inc
OnKure is a clinical-stage oncology company. Its balance sheet is cash flowing for research. Its market capitalization is its hope for success. Its MvsBCap chart is a visualization of biotech risk, where the valuation could soar or collapse based on data from the next stage of clinical trials.
Market to book capitalization ratio in a market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing oncology drugs. Its value is determined by the potential of its scientific research. The chart shows how investors assess its pipeline and the likelihood of success in clinical trials.
Market to book capitalization ratio for the market as a whole
OnKure Therapeutics is a biotech company focused on cancer treatment. Its market value depends almost entirely on the success of its research in clinical trials. This chart is a classic example of biotech, where investors are buying not tangible assets, but the hope of developing a new, effective drug.
Debts of the company, segment and market as a whole
OKUR - Company debts OnKure Therapeutics Inc
OnKure, a clinical-stage oncology company, is devoting all its capital to developing a new class of targeted drugs. Until successful trials or a partnership with major pharma, the company is entirely dependent on external funding. This chart shows how the company manages its resources in the long and risky race to develop a new cancer cure.
Market segment debts - Cancer cure
OnKure Therapeutics is a clinical-stage biotech company focused on developing targeted cancer therapies. Funding cancer research is extremely expensive. This chart shows how the company manages its capital to advance its innovative molecules through the complex stages of clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OnKure Therapeutics Inc
OnKure Therapeutics, like many biotech companies, is focused on developing cancer drugs. This chart demonstrates its critical dependence on external funding to conduct expensive clinical trials. High debt fuels research, but it also poses a huge risk if the drug fails to prove effective.
Market segment debt to market segment book capitalization - Cancer cure
OnKure Therapeutics is a clinical-stage oncology company developing cancer treatments. This chart shows the level of leverage in the biotech sector. It allows one to assess how the company's financial strategy for raising capital for expensive research compares with the practices of other players in the field.
Debt to book value of all companies in the market
OnKure Therapeutics is a biotech company developing targeted therapies for cancer treatment. The overall debt burden, reflected in this chart, shapes the investment climate. For clinical-stage companies requiring ongoing funding, capital availability and investor risk appetite are vital.
P/E of the company, segment and market as a whole
P/E - OnKure Therapeutics Inc
This chart of OnKure Therapeutics, an oncology company, reflects investors' faith in its scientific approach to cancer treatment. Its high stock price reflects the hope that its drugs in development will be successful and offer new options for patients with difficult-to-treat tumors.
P/E of the market segment - Cancer cure
This chart shows the average price-to-earnings ratio for the biotech sector in which OnKure Therapeutics is developing. The industry's very high valuation reflects hopes for breakthroughs in cancer treatment. This metric provides a backdrop against which investors evaluate the scientific potential and risks associated with OnKure's oncology portfolio.
P/E of the market as a whole
OnKure Therapeutics is an oncology company developing targeted therapies that target specific mutations that cause cancer. This approach is precision medicine. This chart shows overall investor interest in oncology. It provides insight into how the market views OnKure's scientific platform and its ability to create effective drugs for specific patient groups, representing the cutting edge of cancer treatment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OnKure Therapeutics Inc
OnKure Therapeutics is an oncology company developing targeted drugs for cancer treatment. Its value is dependent on the success of its clinical trials. This chart reflects analysts' belief that the company's scientific approach will lead to the development of effective drugs that can carve out a niche in the competitive oncology market.
%20P%2FE%20OnKure%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OnKure-Therapeutics-Inc&v=1772688696209 "Chart of the company's future (projected) P/E OnKure Therapeutics Inc")
Future (projected) P/E of the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing targeted cancer therapies focused on hard-to-reach targets. This chart shows analysts' estimates of its future revenue, reflecting their confidence in its scientific approach and potential to create a new class of oncology drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772688696210 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
OnKure Therapeutics is a clinical-stage oncology company. Its future depends on the success of its scientific developments. This chart, reflecting the overall investment climate, serves as an indicator of the company's funding availability. During periods of market optimism, investors are more willing to invest in risky but potentially highly profitable biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772688696223 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OnKure Therapeutics Inc
OnKure Therapeutics Inc. is a biotechnology company developing targeted cancer therapy drugs. Its financial activity is based on investments in clinical trials. The chart illustrates the capital burn required to create a new generation of drugs that selectively target cancer cells while minimizing damage to healthy tissue.
Profit of companies in the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing targeted therapies for the treatment of cancers resistant to existing therapies. Its approach is based on the inhibition of histone deacetylases (HDACs). This graph reflects the high potential in oncology, where overcoming drug resistance is one of the main challenges facing researchers.
Overall market profit
OnKure Therapeutics is a clinical-stage oncology company. Its value is based on expectations of future breakthroughs. The availability of capital to fund research is directly dependent on the overall health of financial markets, which is closely linked to corporate earnings dynamics, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OnKure Therapeutics Inc
OnKure Therapeutics is a biopharmaceutical company developing a new generation of targeted therapies for cancer treatment. The company targets difficult-to-treat mutations. This chart reflects analyst expectations, which are essentially an estimate of the likelihood of success of its clinical programs and future commercial potential.
%20profit%20of%20the%20company%20OnKure%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OnKure-Therapeutics-Inc&v=1772688696240 "Graph of future (projected) profit of the company OnKure Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Cancer cure
OnKure Therapeutics is a biotech company developing targeted drugs for cancer treatment. Its approach is based on the creation of histone deacetylase (HDAC) inhibitors, which may be effective against certain tumor types. This chart shows profitability forecasts for the biotech sector, providing insight into the overall investment climate in precision oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772688696241 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
OnKure Therapeutics is a biotech company developing targeted drugs for cancer treatment. Its growth depends entirely on the success of its research and its ability to attract funding. This chart, reflecting overall market sentiment, influences investor willingness to invest in high-risk but potentially highly profitable oncology projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772688696266 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OnKure Therapeutics Inc
OnKure Therapeutics is a biotech company specializing in cancer treatment. For a clinical-stage company, this chart is a measure of faith in its science. Market value reflects not current sales, but the potential value of its innovative treatment approaches.
P/S market segment - Cancer cure
OnKure Therapeutics Inc. is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of oncology diseases. This chart reflects the average revenue estimate in the biotech sector. It provides an indication of how highly investors value the potential future revenue from OnKure's innovative approach to developing anticancer drugs.
P/S of the market as a whole
OnKure Therapeutics is a clinical-stage oncology company developing targeted therapies that target specific mutations in cancer cells. Their approach is personalized medicine. This chart, reflecting the valuation of companies with actual revenue, serves as a benchmark for understanding the enormous hopes investors have for biotech startups in the oncology field.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OnKure Therapeutics Inc
OnKure Therapeutics is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. This chart illustrates market expectations for its research. The company's valuation is based on the potential of its product candidates to successfully complete clinical trials and offer new options for cancer patients.
%20P%2FS%20OnKure%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OnKure-Therapeutics-Inc&v=1772688696324 "The graph of the company's future (projected) P/S OnKure Therapeutics Inc")
Future (projected) P/S of the market segment - Cancer cure
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for cancer treatment. Its approach is based on inhibiting key enzymes involved in tumor growth. This chart shows how the market values its research compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772688696331 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
OnKure Therapeutics is a clinical-stage oncology company. Its value is based entirely on the potential of its scientific developments. This chart, reflecting the overall investment climate and risk appetite, is critical for OnKure. Market optimism is essential for such companies to attract funding for their long-term, capital-intensive research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772688696332 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OnKure Therapeutics Inc
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for cancer treatment. This chart shows its financial flows, which at this stage likely consist of research funding and partner payments. It illustrates investments in the development of next-generation oncology drugs.
Sales of companies in the market segment - Cancer cure
OnKure Therapeutics Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer. Like many development-stage companies in this industry, its activities are segmented into various drug development programs. This chart depicts the financial flows associated with one of its key research areas.
Overall market sales
OnKure Therapeutics Inc. is a biotechnology company focused on developing innovative drugs for the treatment of cancer. Like other companies in this field, its value is determined by the potential of its scientific developments. It is part of an innovative ecosystem that strives to solve one of humanity's greatest challenges, and its success is not dependent on short-term economic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OnKure Therapeutics Inc
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing next-generation targeted therapies for the treatment of cancers resistant to existing therapies. Its future sales forecast is based on the success of its clinical programs and the ability of its drugs to overcome tumor drug resistance mechanisms.
%20sales%20of%20the%20company%20OnKure%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OnKure-Therapeutics-Inc&v=1772688696371 "Schedule of future (projected) sales of the company OnKure Therapeutics Inc")
Future (projected) sales of companies in the market segment - Cancer cure
OnKure Therapeutics is an oncology company developing targeted cancer treatments. This chart shows aggregate expectations for the entire oncology sector. It helps assess the overall progress in drug discovery, the level of R&D investment, and the commercial potential analysts predict for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772688696377 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
OnKure Therapeutics, a clinical-stage oncology company, depends on its ability to attract capital for costly research. This chart of overall sales forecasts reflects the overall sentiment in financial markets, which determines the availability of funding for biotech startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772688696384 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OnKure Therapeutics Inc
OnKure Therapeutics Inc. is a clinical-stage oncology company developing targeted small-molecule therapies for the treatment of cancer. This chart reflects its financial position, with significant investments in research and development focused on developing a new class of anticancer drugs and achieving future profitability.
Market segment marginality - Cancer cure
OnKure Therapeutics is a biopharmaceutical company focused on developing targeted drugs for cancer treatment. The key to success in this type of business is the ability of their R&D engine to generate promising candidates and advance them through clinical trials at an optimal cost. The chart below shows their operating model.
Market marginality as a whole
OnKure Therapeutics Inc. is an oncology company developing new approaches to cancer treatment. Its future depends on the success of clinical trials. This chart shows the profitability of mature businesses, whereas for OKUR, value lies in the potential of its scientific research to offer patients new, more effective treatments for cancer.
Employees in the company, segment and market as a whole
Number of employees in the company OnKure Therapeutics Inc
OnKure Therapeutics is an oncology company in the preclinical stage. This graph shows its small research team. In the world of biotech, at this stage, what matters is not the size but the quality of the research team conducting experiments that lay the foundation for future clinical trials.
Share of the company's employees OnKure Therapeutics Inc within the market segment - Cancer cure
OnKure Therapeutics is an oncology company developing next-generation targeted therapies. Its research requires a team with deep expertise in cancer chemistry and biology. This metric reflects its commitment to creating more effective and less toxic treatments.
Number of employees in the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing targeted cancer therapies. This chart, which shows the company's work in the oncology sector, demonstrates the scale of its R&D activity. The growing number of scientists in this field demonstrates a deep understanding of the molecular mechanisms of cancer, enabling the creation of highly targeted drugs like those being developed by OnKure.
Number of employees in the market as a whole
OnKure Therapeutics is an oncology company, and its growth depends on clinical success. This graph reflects overall workload, but for OnKure, publishing positive trial results could be a catalyst for attracting investment and hiring dozens of new scientists, regardless of the economic climate.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OnKure Therapeutics Inc (OKUR)
OnKure, Inc. is a biopharmaceutical company developing targeted cancer treatments. This chart likely shows a very high market capitalization per employee. This reflects investors' faith in the company's scientific platform and the potential for its developments to generate billions in future revenues.
%20of%20the%20company%20OnKure%20Therapeutics%20Inc%20(OKUR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OnKure-Therapeutics-Inc-OKUR&v=1772688696473 "Chart of market capitalization per employee (in thousands of dollars) of the company OnKure Therapeutics Inc (OKUR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
OnKure Therapeutics Inc. is a biopharmaceutical company developing targeted therapies for cancer treatment. In oncology, market value per employee directly reflects investors' assessment of the company's scientific potential and clinical development prospects. It is an indicator of the value of its team and intellectual property.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772688696479 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
OnKure Therapeutics Inc. (OKUR) is a clinical-stage biotechnology company developing targeted therapies for cancer treatment. Its future depends on the success of clinical trials. The chart reflects the market's speculative valuation of the intellectual capital of its research team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772688696487 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OnKure Therapeutics Inc (OKUR)
OnKure Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of precision cancer drugs (targeted therapies). This graph (negative) shows R&D intensity. It measures how much capital the company "burns" for each scientist working on discovering and testing the next generation of oncology drugs.
%20Chart%20OnKure%20Therapeutics%20Inc%20(OKUR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OnKure-Therapeutics-Inc-OKUR&v=1772688696488 "Company Profit Per Employee (in thousands of dollars) Chart OnKure Therapeutics Inc (OKUR)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
OnKure Therapeutics is a biopharmaceutical company developing targeted therapies for cancer. In this field, the efficiency and speed of clinical trials determine success. This graph shows the value created by their scientific team and compares their R&D productivity with that of other oncology companies.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772688696493 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
OnKure Therapeutics (OKUR) is a biotech R&D company focused on oncology. Like others, it has no commercial products. This negative metric reflects the cost of maintaining a top-notch scientific team. It shows investors the extent of their investment in the personnel working on developing future breakthrough drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772688696497 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OnKure Therapeutics Inc (OKUR)
OnKure Therapeutics is a clinical-stage oncology company. Its current revenue, if any, likely comes from partnerships. This graph is a bet on the future success of its clinical programs, which could lead to a sharp increase in revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OnKure-Therapeutics-Inc-OKUR&v=1772688696503 "Sales chart per company employee OnKure Therapeutics Inc (OKUR)")
Sales per employee in the market segment - Cancer cure
OnKure Therapeutics is an oncology company developing histone deacetylase (HDAC) inhibitors for cancer treatment. This chart compares revenue per employee (R&D) to the industry average. For an R&D company, this reflects how productive their scientific platform is, possibly in the form of affiliate fees.
Sales per employee for the market as a whole
OnKure Therapeutics (OKUR) is a clinical-stage biotech developing a new generation of PI3K inhibitors for cancer treatment. It is an R&D company with no commercial sales revenue. This graph will show $0, which is typical for a biotech at this stage whose research staff is focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company OnKure Therapeutics Inc (OKUR)
OnKure Therapeutics (OKUR) is an oncology company working on targeted therapies. It's another biotech "lottery." This chart shows the number of investors skeptical of the company's scientific platform and its chances of standing out among hundreds of other oncology startups.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OnKure-Therapeutics-Inc-OKUR&v=1772688696540 "Short Shares Chart for the Company OnKure Therapeutics Inc (OKUR)")
Shares shorted by market segment - Cancer cure
OnKure Therapeutics is an oncology company developing small-molecule inhibitors for cancer treatment. They target specific mutations in tumors. This chart shows the odds against the oncology biotech sector. It reflects the general pessimism among investors and the high probability of clinical trial failure for this type of company.
Shares shorted by the overall market
OnKure Therapeutics is an early-stage biotech company searching for cancer treatments. This chart illustrates the overall market "fear." For investors, this is a risky bet on science. When fear dominates, the market distrusts such companies, fearing they will burn through all their cash on R&D and fail to raise new funding rounds.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OnKure Therapeutics Inc (OKUR)
OnKure Therapeutics is an oncology company developing targeted therapies. Like many early-stage biotechs, the company's stock is highly volatile. This oscillator measures investor sentiment: it shows when positive trial data leads to an "overbought" (above 70) or when delays lead to an "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OnKure-Therapeutics-Inc-OKUR&v=1772688696577 "RSI 14 indicator chart for the company's stock OnKure Therapeutics Inc (OKUR)")
RSI 14 Market Segment - Cancer cure
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for the treatment of cancer. This chart shows the overall "temperature" in the volatile oncology biotech sector. It helps distinguish the dynamics of OnKure from the general "hype" or "disappointment" that has gripped the entire industry.
RSI 14 for the overall market
OnKure Therapeutics (OKUR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OKUR (OnKure Therapeutics Inc)
OnKure (OKUR) is a clinical-stage biotech developing precision (targeted) cancer treatments. This chart shows the speculative average price target from analysts, which is almost entirely based on their assessment of the company's clinical trial success rate and the commercial potential of its R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OKUR-OnKure-Therapeutics-Inc&v=1772688696591 "A chart showing analyst consensus forecasts for the expected stock price. OKUR (OnKure Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price OKUR (OnKure Therapeutics Inc)
OnKure Therapeutics is a clinical-stage biotech developing targeted small-molecule drugs (inhibitors) for cancer treatment. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the company's scientific platform and the success of its R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OKUR-OnKure-Therapeutics-Inc&v=1772688696599 "A chart showing the difference between the consensus forecast and the actual stock price. OKUR (OnKure Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
OnKure (OKUR) is a clinical-stage biotech company developing precision (targeted) cancer treatments. This is a high-risk R&D business. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe in new breakthroughs or anticipate a "winter" in biotech funding.
Analysts' consensus forecast for the overall market share price
OnKure Therapeutics (OKUR) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OnKure Therapeutics Inc
OnKure Therapeutics is a clinical-stage biotech company focused on developing precision (targeted) drugs for cancer treatment. It's a binary risk business: it's all or nothing. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Cancer cure
OnKure Therapeutics (OKUR) is a biopharmaceutical company developing precision cancer treatments. They focus on histone deacetylase (HDAC) inhibitors, striving to create more targeted and less toxic drugs. The chart shows the segment average, helping investors assess how OnKure's risks and potential compare to the drug development sector average.
The AKIM Index for the overall market
OnKure Therapeutics is a biotech company specializing in the discovery and development of precision cancer drugs (mutant protein inhibitors). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to overall economic trends.
